Loading organizations...
MingMed Biotechnology Co., Ltd. specializes in the in-house discovery and development of novel pharmaceutical drugs addressing global unmet medical needs. The company builds a diversified product portfolio across four key therapeutic areas: ophthalmic drugs, recombinant botulinum toxin, immuno-oncology drugs, and pet immune drugs. Its technical approach centers on robust R&D led by experienced scientists, focused on bringing first-in-class drug candidates toward commercialization.
The company was founded in 2019 by a team including Mingguo Huang, Yan Zhang, Xuebin Liao, Fred Ou Yang, Miao Liu, Lai Wei, and Ming Jin. Their collective insight stemmed from a recognition of significant gaps in existing medical treatments, prompting the establishment of MingMed to innovate and develop therapeutic solutions. This diverse group of founders, with their scientific backgrounds, coalesced to create a platform for advanced biotechnological research and development.
MingMed targets a broad range of customers, including patients seeking treatments for ophthalmic conditions and cancer, individuals utilizing recombinant botulinum toxin, and pet owners requiring specialized immune therapies. The company’s long-term vision is to deeply explore the underlying causes of disease, translating this fundamental understanding into the creation of superior medicines. It aims to significantly improve human and animal health through sustained scientific innovation and product development.
MingMed has raised $110.0M across 2 funding rounds.
MingMed has raised $110.0M in total across 2 funding rounds.
MingMed has raised $110.0M across 2 funding rounds. Most recently, it raised $50.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2021 | $50M Series A | — | Gaorong Capital, Lightspeed China Partners | Announced |
| Mar 1, 2021 | $60M Series A | — | Gaorong Capital, Lightspeed China Partners | Announced |
MingMed Biotechnology Co., Ltd. is a clinical-stage biopharmaceutical company based in Guangzhou, China, focused on the in-house discovery and development of novel drugs addressing global unmet medical needs.[1][2][3] It builds a portfolio of first-in-class candidates across four synergistic therapeutic areas: ophthalmic drugs, recombinant botulinum toxin, immuno-oncology drugs, and pet immune drugs, with major products in clinical stages and nearing commercialization.[1][2][5] MingMed serves pharmaceutical sectors needing innovative solutions for conditions like age-related macular degeneration, macular dystrophy, glabellar frown lines, and solid tumors, solving unmet needs through efficient R&D led by top global scientists.[1][3][5] Founded in 2019, it has raised $110M in funding, including a $50M Series A-II round four years ago, signaling strong growth momentum in China's booming biotech ecosystem.[3]
MingMed was founded in October 2019 in Guangzhou's Nansha District by a team including Mingguo Huang, Yan Zhang, and Xuebin Liao, leveraging their expertise to pioneer original drug development.[3][4] The idea emerged amid China's push for innovative pharmaceuticals, with the company establishing headquarters in Guangdong Medical Valley to capitalize on the region's biomedical talent pool of over 58,000 R&D personnel.[3] Early traction came swiftly through internal R&D capabilities, building a pipeline of clinical-stage assets; by 2025, programs like QA108 (Phase 3 for age-related macular degeneration) and YY003 (Phase 2 for glabellar frown lines) demonstrate pivotal progress, including ongoing trials starting as recently as July 2025.[5]
MingMed stands out in biotech through these key strengths:
MingMed rides China's biomedical boom, particularly Guangdong's drive to create a 1 trillion yuan industry cluster amid the Greater Bay Area's (GBA) emphasis on biotech innovation.[3] Its timing aligns with national priorities for original, first-in-class drugs over generics, fueled by talent influx, foreign investment ease in hubs like Hong Kong, and policy support for basic research.[3] Market forces like rising demand for ophthalmology, oncology, and aesthetic treatments favor its pipeline, while it influences the ecosystem by validating GBA as a drug discovery hotspot—exemplified by executive insights on Hong Kong's role in funding high-return innovations.[3] This positions MingMed as a bridge between China's manufacturing scale and global unmet needs.
MingMed is poised for commercialization milestones, with Phase 3 assets like QA108 potentially launching soon and new trials (e.g., Phase 1/2 oncology in 2025) expanding its reach.[5] Trends like AI-aided discovery, GBA integration, and global demand for novel biologics will accelerate its trajectory, potentially evolving it into a multi-billion player via partnerships or IPOs. As a 2019-founded trailblazer raising $110M early, MingMed exemplifies how targeted R&D in synergistic areas can redefine China's pharma presence, delivering drugs that truly address unmet needs.[1][3]
MingMed has raised $110.0M in total across 2 funding rounds.
MingMed's investors include Gaorong Capital, Lightspeed China Partners.
